RenovoRx (RNXT) Share-based Compensation (2020 - 2026)
RenovoRx (RNXT) posted Share-based Compensation of $1.8 million for Q1 2026, up 531.58% sequentially from $285000.0 in Q4 2025, and up 525.0% YoY from $288000.0 in Q1 2025.
RenovoRx (RNXT) Share-based Compensation (2020 - 2026) Analysis & Trends
RenovoRx has reported Share-based Compensation for 7 years, with the latest figure at $1.8 million in Q1 2026.
- Quarterly Share-based Compensation rose 525.0% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 1100.0% YoY) and the FY2025 annual result came in at $2.1 million, up 16.67% from the prior year.
- Share-based Compensation climbed to $1.8 million in Q1 2026 per RNXT's latest filing, from $285000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.8 million in Q1 2026 and troughed at -$637000.0 in Q4 2024.
- A 5-year average of $298470.6 and a median of $255000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation soared 2314.29% in 2022, then plunged 388.24% in 2024.
- Over 5 years, Share-based Compensation stood at $164000.0 in 2022, then soared by 34.76% to $221000.0 in 2023, then slumped by 388.24% to -$637000.0 in 2024, then soared by 144.74% to $285000.0 in 2025, then surged by 531.58% to $1.8 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.8 million, $285000.0, and $349000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.00 Mn |
| Jun 30, 2026 | 3.00 Mn |
| Mar 31, 2026 | 1.80 Mn |
| Mar 31, 2026 | 1.80 Mn |
| Dec 31, 2025 | 285,000.00 |
| Dec 31, 2025 | 285,000.00 |
| Sep 30, 2025 | 349,000.00 |
| Sep 30, 2025 | 349,000.00 |
| Jun 30, 2025 | 345,000.00 |
| Jun 30, 2025 | 345,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Dec 31, 2024 | -637,000.00 |
| Dec 31, 2024 | -637,000.00 |
| Sep 30, 2024 | 255,000.00 |
| Sep 30, 2024 | 255,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Mar 31, 2024 | 423,000.00 |
| Mar 31, 2024 | 423,000.00 |